HC Wainwright Issues Negative Forecast for ETON Earnings

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) – HC Wainwright dropped their Q1 2025 EPS estimates for Eton Pharmaceuticals in a report released on Wednesday, November 13th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings of $0.09 per share for the quarter, down from their previous forecast of $0.12. HC Wainwright currently has a “Buy” rating and a $11.00 target price on the stock. The consensus estimate for Eton Pharmaceuticals’ current full-year earnings is ($0.17) per share. HC Wainwright also issued estimates for Eton Pharmaceuticals’ Q2 2025 earnings at $0.09 EPS, Q3 2025 earnings at $0.12 EPS, Q4 2025 earnings at $0.14 EPS, FY2026 earnings at $0.85 EPS, FY2027 earnings at $1.13 EPS and FY2028 earnings at $1.28 EPS.

Separately, Craig Hallum upped their price target on Eton Pharmaceuticals from $10.00 to $15.00 and gave the stock a “buy” rating in a report on Monday, October 28th.

Eton Pharmaceuticals Stock Down 4.2 %

Shares of Eton Pharmaceuticals stock opened at $10.02 on Friday. Eton Pharmaceuticals has a 52 week low of $3.03 and a 52 week high of $11.11. The business has a 50 day moving average price of $7.40 and a 200-day moving average price of $4.98. The company has a market cap of $258.92 million, a PE ratio of -45.55 and a beta of 1.25.

Insider Buying and Selling

In other Eton Pharmaceuticals news, major shareholder Opaleye Management Inc. acquired 11,248 shares of the business’s stock in a transaction on Monday, October 7th. The shares were acquired at an average price of $7.22 per share, with a total value of $81,210.56. Following the completion of the transaction, the insider now owns 2,730,000 shares in the company, valued at approximately $19,710,600. This trade represents a 0.41 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Over the last ninety days, insiders have bought 85,600 shares of company stock worth $462,674. 14.89% of the stock is owned by insiders.

Institutional Investors Weigh In On Eton Pharmaceuticals

Large investors have recently made changes to their positions in the business. Parkman Healthcare Partners LLC boosted its holdings in shares of Eton Pharmaceuticals by 2.8% in the 3rd quarter. Parkman Healthcare Partners LLC now owns 260,226 shares of the company’s stock worth $1,561,000 after buying an additional 7,029 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new position in Eton Pharmaceuticals in the third quarter valued at about $54,000. Westside Investment Management Inc. grew its position in shares of Eton Pharmaceuticals by 2.0% during the 2nd quarter. Westside Investment Management Inc. now owns 585,400 shares of the company’s stock valued at $1,926,000 after acquiring an additional 11,440 shares during the period. Jane Street Group LLC bought a new position in shares of Eton Pharmaceuticals during the 3rd quarter valued at approximately $90,000. Finally, Acadian Asset Management LLC increased its stake in shares of Eton Pharmaceuticals by 13.7% during the 1st quarter. Acadian Asset Management LLC now owns 156,386 shares of the company’s stock worth $585,000 after purchasing an additional 18,898 shares during the last quarter. 27.86% of the stock is owned by hedge funds and other institutional investors.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.